CRIS Current Research Information System

PILERI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.406
EU - Europa 13.674
AS - Asia 13.426
SA - Sud America 1.044
AF - Africa 897
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 23
Totale 49.494
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.236
SG - Singapore 4.166
GB - Regno Unito 4.160
CN - Cina 4.094
VN - Vietnam 2.351
DE - Germania 1.869
IT - Italia 1.645
SE - Svezia 1.598
UA - Ucraina 1.026
HK - Hong Kong 1.001
RU - Federazione Russa 895
IN - India 886
BR - Brasile 773
FR - Francia 622
IE - Irlanda 496
ZA - Sudafrica 377
EE - Estonia 300
KR - Corea 248
JP - Giappone 246
CH - Svizzera 230
CI - Costa d'Avorio 192
NL - Olanda 183
FI - Finlandia 140
TG - Togo 139
AR - Argentina 127
CA - Canada 93
SC - Seychelles 87
JO - Giordania 77
HR - Croazia 73
BE - Belgio 68
BG - Bulgaria 64
ID - Indonesia 62
GR - Grecia 60
IR - Iran 57
AT - Austria 55
MX - Messico 52
LB - Libano 45
NG - Nigeria 44
EC - Ecuador 41
PL - Polonia 39
BD - Bangladesh 34
TR - Turchia 33
CL - Cile 31
ES - Italia 30
LU - Lussemburgo 30
CO - Colombia 22
EU - Europa 17
IQ - Iraq 17
UZ - Uzbekistan 16
LT - Lituania 15
PY - Paraguay 14
EG - Egitto 13
PE - Perù 13
MY - Malesia 12
RO - Romania 12
TN - Tunisia 12
PK - Pakistan 11
AU - Australia 10
DO - Repubblica Dominicana 10
NZ - Nuova Zelanda 10
PT - Portogallo 10
UY - Uruguay 10
VE - Venezuela 10
CZ - Repubblica Ceca 9
AE - Emirati Arabi Uniti 8
PH - Filippine 8
DK - Danimarca 7
TW - Taiwan 7
AL - Albania 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
IL - Israele 5
MA - Marocco 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
CR - Costa Rica 4
DZ - Algeria 4
ET - Etiopia 4
HU - Ungheria 4
KZ - Kazakistan 4
SA - Arabia Saudita 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
GE - Georgia 3
HN - Honduras 3
IS - Islanda 3
KH - Cambogia 3
KW - Kuwait 3
NO - Norvegia 3
NP - Nepal 3
AO - Angola 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CU - Cuba 2
GA - Gabon 2
KE - Kenya 2
KG - Kirghizistan 2
MK - Macedonia 2
NC - Nuova Caledonia 2
Totale 49.456
Salva come PNG Salva come JPEG
Città #
Southend 3.699
Fairfield 2.741
Singapore 2.614
Ashburn 1.848
Woodbridge 1.379
Chandler 1.266
Houston 1.255
Seattle 1.202
Wilmington 1.201
Hong Kong 987
Cambridge 981
Princeton 882
Ann Arbor 813
Dong Ket 694
Jacksonville 639
Hefei 621
Santa Clara 539
Boardman 496
Dublin 494
Beijing 460
Nanjing 415
Westminster 382
Padova 374
Ho Chi Minh City 352
Los Angeles 281
Hanoi 270
Bologna 243
Seoul 238
Tokyo 236
Berlin 226
Saint Petersburg 204
Jinan 196
Buffalo 193
Bern 192
Abidjan 191
Milan 176
New York 172
Shenyang 164
Mülheim 146
Nanchang 143
San Diego 141
Lomé 138
Hebei 133
Changsha 120
Helsinki 115
Bremen 112
Tianjin 106
Dallas 98
Redondo Beach 91
Jiaxing 87
Zhengzhou 83
São Paulo 81
Guangzhou 79
Amman 77
Hangzhou 72
Medford 71
Mahé 69
Chicago 62
Sofia 62
Brussels 61
Dearborn 60
Turin 59
Bengaluru 58
Shanghai 58
Ningbo 56
Munich 55
Norwalk 55
Phoenix 55
Taizhou 55
Redwood City 54
Frankfurt am Main 53
Hyderabad 52
Falls Church 50
Haikou 49
Olalla 49
San Venanzo 49
Yubileyny 49
Rome 45
Taiyuan 44
The Dalles 44
Abeokuta 42
Verona 42
Toronto 41
Des Moines 40
Haiphong 40
Redmond 40
London 37
Lanzhou 34
Nuremberg 32
Fuzhou 28
Da Nang 27
Wuhan 27
Moscow 26
Bühl 25
Kunming 25
Amsterdam 24
Biên Hòa 24
Fremont 24
Montreal 24
Paris 24
Totale 33.138
Salva come PNG Salva come JPEG
Nome #
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 280
Biology and treatment of follicular lymphoma. 264
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 261
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 254
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 241
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 241
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 231
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 226
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 226
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 226
B-cells and mixed cryoglobulinemia. 222
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 221
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 218
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 216
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 216
B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. 212
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 208
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 208
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 207
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 207
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 206
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 203
T-Cell Lymphomas in South America and Europe 202
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 200
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 199
IFI16 expression is related to selected transcription factors during B-cell differentiation 196
Expression of CD52 in peripheral T-cell lymphoma. 195
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. 192
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 190
Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change 189
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 184
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 183
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 182
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 182
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. 181
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 181
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 181
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. 179
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 175
Histopathology of B-cell chronic lymphocytic leukemia. 174
A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. 174
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 174
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 174
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 173
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 172
CD30 expression in peripheral T-cell lymphomas 172
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 171
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 171
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 170
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 170
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 169
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 168
CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. 168
Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. 168
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 168
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 168
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 168
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 167
Anaplastic Large Cell Lymphoma: a critical reappraisal 166
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 166
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 165
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 165
BCL10 down-regulation in peripheral T-cell lymphomas. 160
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma 159
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 159
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 159
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 159
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 159
A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. 158
Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas 158
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 157
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 157
Pathobiology of hodgkin lymphoma. 157
Aberrant promoter methylation of multiple genes thoughout the clinico-pathologic spectrum of B-cell neoplastia. 156
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 156
Small bowel obstruction caused by a large B-cell lymphoma in a patient with multicentric Castleman’s disease: an unusual occurrence 156
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 156
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus 156
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 155
Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. 154
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary - Neoplasia a cellule dendritiche plasmocitoidi blastiche: il santuario cutaneo 154
BCL10 expression in peripheral T-Cell lymphoma not otherwise specified. 152
Enteropathy-associated T-cell lymphoma. 152
Molecular genetics of peripheral T-cell lymphomas 152
Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. 151
Molecular profiling of aggressive lymphomas 151
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 150
Pathobiology of anaplastic large cell lymphoma. 150
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 149
CD27 distingishes two phases in bone marrow infiltration of splenic marginal zone lymphoma. 148
High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. 148
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 148
WHO Classification of Tumours of Haematopoietic and Lymphoid tissues. 148
Relationship between dyskerin expression and telomerase activity in human breast cancer. 147
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. 147
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 147
Simple diagnostic assay for hairy cell leukemia by cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 146
Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells. 146
Targeted molecular therapy in peripheral T-cell lymphomas 146
Totale 17.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.291 0 0 0 0 0 336 59 286 508 286 259 1.557
2021/20226.593 706 232 540 573 677 381 142 449 247 394 1.258 994
2022/20236.393 847 864 353 789 458 472 221 332 1.011 174 504 368
2023/20241.590 89 290 108 174 142 290 109 94 48 128 54 64
2024/20256.621 217 1.297 583 463 1.044 373 562 158 71 330 251 1.272
2025/20268.372 1.043 1.619 1.650 1.322 1.853 885 0 0 0 0 0 0
Totale 50.236